靶向免疫治疗在肾脏疾病中的应用:小型战士,巨大影响
本文综述靶向B细胞的创新免疫疗法(CAR-T细胞与T细胞衔接器)在肾脏疾病中的应用。CD19+ CAR-T细胞在难治性系统性红斑狼疮病例系列中显示可清除自身反应性B细胞并实现临床缓解,但肾脏疾病数据有限。综述总结肾脏特异性应用与副作用,并展望新兴免疫治疗方向。
要点
- CD19+ CAR-T在难治性SLE病例系列中显示清除自身反应性B细胞并实现临床缓解。
- 自身反应性B细胞也介导ANCA相关血管炎、膜性肾病和IgA肾病等炎症性肾病。
- 肾脏疾病中这些新疗法的数据有限,需评估蛋白尿、eGFR等肾脏终点。
核心结论
- 靶向B细胞的新型免疫疗法在肾脏疾病中可能比传统抗CD20抗体更有效清除自身反应性B细胞并持续抑制自身免疫,但肾脏疾病数据仍有限。
研究设计与样本
- 综述:总结同种异体和自体CAR-T细胞及T细胞衔接器在肾脏疾病中的应用与副作用。
主要发现
- 靶向T细胞衔接器或B细胞导向CAR-T治疗自身免疫病的有效性目前仅在不设对照的研究者发起试验中证实。
- 难治性系统性红斑狼疮的病例系列显示CD19+ CAR-T细胞有效且安全,可清除自身反应性B细胞并实现完全临床缓解。
- 许多患者对现有治疗无应答,导致疾病进展或复发率高。
关键数值与推荐
- 肾脏疾病应用数据有限,需研究蛋白尿减少、eGFR稳定、组织学改善和疾病缓解率等临床相关肾脏终点。
临床怎么用
- 在自身免疫性肾脏疾病中可考虑新型B细胞靶向免疫治疗,但需在临床研究中评估肾脏终点。
局限性
- 靶向免疫治疗在肾脏疾病中的应用数据仍有限。
- 有效性证据目前仅来自不设对照的研究者发起试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advances in immunotherapy targeting B cells have ushered in a new era for disease treatment. The effectiveness of targeted approaches such as T-cell engagers or B cell-directed chimeric antigen receptor (CAR)-T-cell therapy in treating autoimmune diseases has been demonstrated so far only in uncontrolled, investigator-initiated trials. Several case series in patients with therapy-resistant systemic lupus erythematosus showed efficacy and safety of CD19+ CAR-T cells, showing depletion of autoreactive B cells and full clinical remission. Autoreactive B cells not only mediate pathogenesis of systemic lupus erythematosus and lupus nephritis, but also many other inflammatory kidney diseases such as antineutrophil cytoplasmic antibody-associated vasculitis, membranous nephropathy, and IgA-associated nephropathy. Moreover, many patients do not respond to currently used treatment options, resulting in a high rate of disease progression or recurrence. Thus, implementing novel B cell-targeting immunotherapies in kidney diseases could lead to a more effective depletion of autoreactive B cells and sustained suppression of autoimmunity than conventional anti-CD20 antibody therapy. However, data on the application of these approaches in kidney diseases remain limited. Therefore, it is important to investigate their effects on clinically relevant kidney endpoints, such as proteinuria reduction, stabilization of estimated glomerular filtration rate, histologic improvements, and rates of disease remission, particularly in the context of autoimmune kidney diseases. This review provides a summary of kidney-specific applications and side effects associated with novel immunotherapies, including allogeneic and autologous CAR-T cells and T-cell engagers, and offers a perspective on emerging immunotherapeutic approaches.
引用
- Kurzhagen JT, Laqua W, Schett G, et al. Tiny warriors, big impact: targeted immunotherapy in kidney diseases. Kidney Int. 2026. PMID: 41765179. doi:10.1016/j.kint.2026.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。